General Inception announces the launch of Igniter Europe,
focused on building innovative companies in the field of oncology,
autoimmune and rare diseases, developing novel therapeutics and
leveraging disruptive technology platforms.
PALO
ALTO, Calif. and LYON,
France, April 29, 2024 /PRNewswire-PRWeb/
-- General Inception announces the launch of Igniter Europe,
focused on building innovative companies in the field of oncology,
autoimmune and rare diseases, with novel therapeutics and
disruptive technology platforms that enable accelerated drug
development with data analytics solutions leveraging patients' data
and clinical insights early on in the phase of drug
development.
Since its establishment in the United
States in 2020, General Inception has co-founded over 35
companies across three divisions: (1) Therapeutics, (2) Engineered
Biology, and (3) Life Science Tools & Diagnostics. The company
works closely with renowned researchers and institutions to
facilitate the inception and acceleration of startups. With the
assistance of more than 50 staff and entrepreneurs in residence,
General Inception brings in critical industry expertise and
financial resources to address the fundamental challenges
associated with the building of future market leaders. The team
operates daily on both sides of the Atlantic to streamline the
development of breakthrough solutions for the healthcare
industry.
Igniter Europe will continue
this mission in Europe, leveraging
the unique ecosystem available regionally for startups with the
financial support of France 2030's
French Tech Accélération 2 fund, managed on behalf of the French
government by Bpifrance, KU Leuven, and Paladin Capital Group as
initial investors and strategic partners. Venkat Reddy and François Valencony will
co-manage this industrial holding, bringing together more than 50
years of consolidated experience in the pharmaceutical and life
sciences industry.
Igniter Europe is operational
and already supports five innovative companies:
- Abbelight provides hardware and software solutions for
Super-Resolution Microscopy to leading research centers,
biotechnology and pharmaceutical companies, based on more than 10
years of research conducted at ISMO (Paris Saclay University) and
Langevin Institute (ESPCI). The company is currently expanding its
product offering and also commercially in North America and Asia.
- Ennovate Pharma was recently launched with the aim of
developing innovative treatments for patients who are
non-responders or refractory to current standard of care for
autoimmune and inflammatory diseases.The company utilizes clinical
data and advanced data analytics capabilities to bring more
effective medicines to patients.
- GauDDi is an innovative small molecule drug discovery company
targeting RNA modifications in immune cells for the treatment of
immune-mediated diseases. GauDDi was launched in close
collaboration with Pharmacelera, a Barcelona-based software company that
specializes in computational chemistry with the use of quantum
mechanics algorithms, machine learning, and high-performance
computing.
- Nickl Therapeutics was founded in Grand-Est region,
France in 2023 with a focus on
developing next-generation NK cell and innate lymphoid cell
therapeutics for oncology and auto-immune disease. By utilizing
highly innovative macrocyclic multi-specific cell engagers, Nickl
Therapeutics aims to redirect the cytotoxic capabilities of NK
cells for the precision killing of disease mediating cells across a
number of therapeutic settings. The initial focus is on the
activation of the innate immune system within the microenvironment
of solid tumors to enhance cancer cell killing.
- Tavira Therapeutics is developing a modular next-generation
AAV capsid platform, with the goal of enhancing tissue-specific
transgene delivery for gene therapy. The modularity afforded by the
Tavira platform should not only accelerate the development of novel
therapies, but also streamline AAV vector manufacturing. By
enhancing specificity and reducing immunogenicity, the platform
furthermore addresses toxicities associated with AAV-based gene
therapy. Tavira is leveraging the cutting-edge AAV gene therapy
research and development capabilities of the University of
Leuven.
"We thank our existing and new investors, who help us accelerate
our expansion in Europe. We
believe we can add tremendous value to the European innovation
ecosystem, offering access to our industry expertise, international
network, and financing capabilities," said Paul Conley, CEO and Co-founder of General
Inception.
"We are exceptionally proud of the executives who have joined us
over the last 18 months to expand our footprint on both sides of
the Atlantic. The diversity, quality and commitment of our team
will allow us to build differentiated companies and products in a
capital efficient manner," said François Valencony, Chief Business
Officer and co-manager of Igniter Europe.
"We are thrilled to offer a platform to innovators who can
utilize their scientific expertise to create economic value. We
strongly believe that our approach to founding and managing
companies, in different innovation corridors throughout
Europe, will lead to high-impact
projects and contribute to a more efficient and accessible
healthcare system," stated Venkat
Reddy, Chief Scientific Officer and co-manager of Igniter
Europe.
"Igniter Europe's approach in the field of company creation and
expansion, in close collaboration with General Inception, is quite
original. Thanks to an experienced team and privileged access to
major research institutions, this partnership should enable the
emergence of leading industrial companies in France over the medium term, to which
Bpifrance is delighted to contribute on behalf of the French
government," says Pierre Gillet,
Investment Director of Bpifrance's French Tech Acceleration
fund.
"Our support is based on more than 15 years' experience with the
team as deeptech venture capital investors and a shared conviction
in the value of their mission. Paladin is strongly committed to
advancing digital biology and biosecurity, and we are excited by
the potential of Europe's research
base in these areas of fundamental value to society," added
Mourad Yesayan, Managing Director,
Paladin Capital Group.
Media Contact
Elodie Dormes, General Inception,
1 1234567, communication@generalinception.com,
www.generalinception.com
View original
content:https://www.prweb.com/releases/general-inception-launches-igniter-europe-with-the-support-of-leading-institutions-and-venture-capital-firms-302129656.html
SOURCE General Inception